Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exelixis, Inc.
  6. News
  7. Summary
    EXEL   US30161Q1040


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December

11/03/2021 | 03:11pm EST

- Presentations to be webcast on www.exelixis.com -

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following virtual investor conferences in November and December of 2021:

  • BMO Biopharma Spotlight Series: Oncology: Exelixis is scheduled to present at 12:10 p.m. ET / 9:10 a.m. PT on Monday, November 8.
  • Credit Suisse 30th Annual Virtual Healthcare Conference: Exelixis is scheduled to present at 1:50 p.m. ET / 10:50 a.m. PT on Wednesday, November 10.
  • Stifel 2021 Healthcare Conference: Exelixis is scheduled to present at 4:40 p.m. ET / 1:40 p.m. PT on Tuesday, November 16.
  • Piper Sandler 33rd Annual Virtual Healthcare Conference: Exelixis’ presentation session will be available to view on-demand beginning 10:00 a.m. ET / 7:00 a.m. PT on Monday, November 22.
  • Evercore ISI 4th Annual HealthConX Virtual Conference: Exelixis is scheduled to present at 11:45am ET / 8:45am PT on Wednesday, December 1.

To access the webcast links, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentations to ensure adequate time for any software download that may be required to listen to the webcasts. Replays will also be available at the same location for 14 days.

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor’s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a registered Japanese trademark.

ę Business Wire 2021
All news about EXELIXIS, INC.
01/19Exelixis Reports Trial Results For Cabozantinib in Combination With Immunotherapies to ..
01/18Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapie..
01/18Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapie..
01/10EXELIXIS : Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Prov..
01/10EXELIXIS, INC. : Results of Operations and Financial Condition (form 8-K)
01/10Exelixis Expects Net Product Revenue of $300 Million for Q4, $1.08 Billion for Full-Yea..
01/09Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Pro..
01/09Exelixis, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter a..
01/06Exelixis to Pay $55 Million to Amend Licensing Deal With Iconic Therapeutics, Gains Ful..
01/06Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antib..
More news
Analyst Recommendations on EXELIXIS, INC.
More recommendations
Financials (USD)
Sales 2021 1 342 M - -
Net income 2021 165 M - -
Net cash 2021 1 019 M - -
P/E ratio 2021 33,7x
Yield 2021 -
Capitalization 5 512 M 5 512 M -
EV / Sales 2021 3,35x
EV / Sales 2022 2,70x
Nbr of Employees 773
Free-Float 97,9%
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | EXEL | US30161Q1040 | MarketScreener
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 17,42 $
Average target price 28,85 $
Spread / Average Target 65,6%
EPS Revisions
Managers and Directors
Michael M. Morrissey President-Research & Development
Christopher J. Senner Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Vicki L. Goodman Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
EXELIXIS, INC.-1.97%5 512
WUXI APPTEC CO., LTD.-12.95%47 040
BIONTECH SE-40.05%37 325